Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

49.53
-0.0200-0.04%
Post-market: 49.530.00000.00%16:41 EDT
Volume:593.75K
Turnover:29.44M
Market Cap:3.91B
PE:-10.48
High:50.07
Open:49.11
Low:48.09
Close:49.55
Loading ...

PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?

Zacks
·
04 Feb

Why PTC Therapeutics (PTCT) Stock Is Rallying Today

Insider Monkey
·
04 Feb

Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

TIPRANKS
·
03 Feb

PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald

TIPRANKS
·
03 Feb

PTC Therapeutics (PTCT) Receives a Hold from Leerink Partners

TIPRANKS
·
22 Jan

U.S. RESEARCH ROUNDUP- Apple, Murphy USA, UnitedHealth

Reuters
·
21 Jan

Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

TIPRANKS
·
15 Jan

PTC Therapeutics Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
15 Jan

Cautious Outlook on PTC Therapeutics Amid Regulatory and Financial Challenges

TIPRANKS
·
15 Jan

BRIEF-Orsini Chosen By PTC Therapeutics As Exclusive Specialty Pharmacy Provider For Adeno-Associated Virus Vector-Based Gene Therapy KEBILIDI™

Reuters
·
14 Jan

Orsini: Chosen by PTC Therapeutics as Exclusive Specialty Pharmacy Provider for Adeno-Associated Virus Vector-Based Gene Therapy Kebilidi

THOMSON REUTERS
·
14 Jan

PTC Therapeutics (PTCT) Gets a Sell from Bank of America Securities

TIPRANKS
·
14 Jan

PTC Therapeutics: Strong Financial Performance and Strategic Advancements Justify Buy Rating

TIPRANKS
·
14 Jan

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
14 Jan

PTC Therapeutics Surpasses Expectations with Strong 2024 Financials and Promising 2025 Outlook

TIPRANKS
·
14 Jan

PTC Therapeutics Surpasses Revenue Guidance for 2024

TIPRANKS
·
14 Jan

PTC Therapeutics sees FY25 revenue $600M-$800M, consensus $963.31M

TIPRANKS
·
13 Jan

PTC Therapeutics Inc: Anticipates Total Revenues for Full-Year 2025 to Be Between $600 Mln and $800 Mln

THOMSON REUTERS
·
13 Jan

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43Rd Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
13 Jan

RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating

MT Newswires Live
·
07 Jan